Migraine
📧 Sign up to get email alerts when something new happens for Migraine.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-01-03FDA Approved: DIVALPROEX SODIUM — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for divalproex sodium from Upsher-Smith Laboratories, indicating a regulatory action related to …
-
FDA approval · 2019-12-23FDA Approved: UBRELVY — Original Application (Allergan, Inc.)
The FDA approved UBRELVY (ubrogepant) from Allergan, Inc. as the original application for the acute treatment of migraine in adults. The app…
-
CLINICAL_TRIALS trial_result · 2019-12-23Clinical Trial Update: A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers [Phase 1]
Phase 1 trial assessing M207 with intranasal zolmitriptan in healthy volunteers has been completed with results posted.
-
FDA approval · 2019-12-20FDA Approved: ONZETRA XSAIL — Supplemental Application (Currax Pharmaceuticals LLC)
The FDA approved a supplemental application for ONZETRA XSAIL (sumatriptan succinate) filed by Currax Pharmaceuticals LLC.
-
FDA approval · 2019-12-20FDA Approved: ZOLMITRIPTAN — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for Zolmitriptan from Rising Pharma Holdings, Inc., supporting changes to the generic’s labeling.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-12-17FDA Approved: BUTALBITAL, ACETAMINOPHEN AND CAFFEINE — Original Application (Lannett Company, Inc.)
FDA approved an original ANDA for a generic Butalbital/acetaminophen/caffeine combination (butalbital, acetaminophen and caffeine) by Lannet…
-
FDA approval · 2019-12-06FDA Approved: ZOLMITRIPTAN — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for Zolmitriptan from Alembic Pharmaceuticals Limited, indicating an updated or additional approval …
-
FDA approval · 2019-12-05FDA Approved: EMGALITY — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Emgality (galcanezumab) from Eli Lilly and Company.
-
FDA approval · 2019-12-03FDA Approved: ZOLMITRIPTAN — Supplemental Application (Ajanta Pharma USA Inc.)
FDA lists a supplemental approval for zolmitriptan from Ajanta Pharma USA Inc. under an ANDA, indicating the approval of a supplemental appl…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in the Pediatric Emergency Department [Phase 3]
A Phase 3 clinical trial evaluating oral dexamethasone for treating acute migraine recurrence in pediatric emergency department patients has…
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants [Phase 1]
Phase 1 study evaluating the effect of single oral doses of lasmiditan when coadministered with single oral doses of sumatriptan in healthy …
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine [Phase 2]
Phase 2 trial update for intravenous COL-144 in acute treatment of migraine; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: A Study of Lasmiditan in Participants With Migraine [Phase 1]
Phase 1 clinical trial update for lasmiditan in participants with migraine; study completed with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-12-02Clinical Trial Update: Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function [Phase 1]
Phase 1 study assessing oral lasmiditan in participants with normal and impaired renal function; completed with results posted in 2019.
-
FDA approval · 2019-11-29FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Cipla USA Inc.)
FDA approved Cipla USA Inc.'s supplemental application for Rizatriptan Benzoate as a generic version under ANDA204339.
-
FDA approval · 2019-11-29FDA Approved: RIZATRIPTAN — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Rizatriptan submitted by Macleods Pharmaceuticals Limited.
-
FDA approval · 2019-11-29FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Rizatriptan Benzoate by Macleods Pharmaceuticals Limited. The action adds regulatory approval fo…
-
FDA approval · 2019-11-29FDA Approved: RIZATRIPTAN BENZOATE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application from Unichem Pharmaceuticals (USA), Inc. for Rizatriptan Benzoate, authorizing the marketing of a ge…
-
CLINICAL_TRIALS withdrawal · 2019-11-29Clinical Trial Update: Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department [Phase 4]
A Phase 4 clinical trial on improving migraine outcomes in patients presenting to the Emergency Department has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2019-11-27Clinical Trial Update: Lasmiditan Compared to Placebo in the Acute Treatment of Migraine: [Phase 3]
Phase 3 clinical trial comparing lasmiditan to placebo for acute treatment of migraine has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-11-27Clinical Trial Update: Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function [Phase 1]
Phase 1 pharmacokinetic study of single-dose oral lasmiditan in participants with normal and impaired hepatic function completed; results po…
-
FDA approval · 2019-11-22FDA Approved: DEPAKOTE SPRINKLES — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application to introduce Depakote Sprinkles (divalproex sodium) from AbbVie, expanding the drug's dosage form op…
-
CLINICAL_TRIALS trial_result · 2019-11-01Clinical Trial Update: A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain [Phase 2]
Phase 2 trial update evaluating the efficacy and safety of oral CL-H1T for acute migraine pain has been completed.
-
FDA approval · 2019-10-29FDA Approved: SUMATRIPTAN SUCCINATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Sumatriptan Succinate from Sun Pharmaceutical Industries, Inc., reflecting an approval of a …
-
CLINICAL_TRIALS trial_result · 2019-10-25Clinical Trial Update: The Utility of Telemedicine in the Management of Migraine
A completed clinical trial evaluating the utility of telemedicine in managing migraine headaches.